Viewing Study NCT04118868


Ignite Creation Date: 2025-12-24 @ 5:28 PM
Ignite Modification Date: 2025-12-25 @ 3:02 PM
Study NCT ID: NCT04118868
Status: UNKNOWN
Last Update Posted: 2022-10-12
First Post: 2019-10-04
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Sponsor: Sorrento Therapeutics, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module